Pharmacoeconomic evaluation of omalizumab in the treatment of severe allergic asthma
- VernacularTitle:奥马珠单抗治疗重度过敏性哮喘的药物经济学评价
- Author:
Chaogang XIONG
1
;
Yurong ZHU
2
;
Mengna AN
3
;
Ying LI
1
;
Xin ZHANG
1
;
Shengjie ZHANG
1
;
Kezhen FENG
4
;
Weiyi FENG
3
Author Information
1. Dept. of Pharmacy，Xi’an Chest Hospital，Xi’an 710100，China
2. Dept. of Pharmacy，Gansu Provincial Maternity and Child-care Hospital，Lanzhou 730050，China
3. Dept. of Pharmacy，the First Affiliated Hospital of Xi’an Jiaotong University，Xi’an 710061，China
4. Dept. of Clinical Pharmacy，Shaanxi Second Provincial People’s Hospital，Xi’an 710005，China
- Publication Type:Journal Article
- Keywords:
omalizumab;
severe allergic asthma;
cost-
- From:
China Pharmacy
2024;35(10):1232-1237
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the cost-effectiveness of omalizumab in the treatment of severe allergic asthma from the perspective of healthcare providers in China. METHODS Based on the data from an international multicenter study of omalizumab in the treatment of severe allergic asthma， the Markov model was constructed according to the progression of severe allergic asthma， with a cycle of 4 weeks. Long-term health outcomes and costs of omalizumab combined with standard of care（SoC） regimen versus SoC regimen in the treatment of severe allergic asthma were simulated by using quality-adjusted life years （QALYs） and incremental cost-effectiveness ratio（ICER） as output indexes. One-way sensitivity analysis， probabilistic sensitivity analysis， and scenario analysis were performed to test the robustness of the results. RESULTS Compared with the SoC regimen， ICER for the omalizumab combined with SoC regimen was 107 723.05 yuan/QALY， which was less than the willingness-to-pay（WTP） threshold （268 074 yuan/QALY） calculated by three times per capita gross domestic product（GDP） in China in 2023. The one-way sensitivity analysis showed that the baseline serum level of immunoglobulin E had the greatest impact on the robustness of the model. The probabilistic sensitivity analysis showed that the omalizumab+SoC regimen had a 93.00% probability of being cost- effective. The scenario analysis showed that in the real world， the billing method of omalizumab based on specifications rather than actual usage may increase ICER. CONCLUSIONS Compared with the SoC regimen， the combination of omalizumab and SoC regimen for treating severe allergic asthma is cost-effective， with a WTP threshold of three times China’s per capita GDP
